Zoetis Ebitda Over Time
| ZTS Stock | USD 176.71 1.04 0.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Zoetis Performance and Zoetis Correlation. Zoetis |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zoetis. If investors know Zoetis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zoetis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.163 | Dividend Share 1.671 | Earnings Share 5.32 | Revenue Per Share 20.057 | Quarterly Revenue Growth 0.11 |
The market value of Zoetis Inc is measured differently than its book value, which is the value of Zoetis that is recorded on the company's balance sheet. Investors also form their own opinion of Zoetis' value that differs from its market value or its book value, called intrinsic value, which is Zoetis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zoetis' market value can be influenced by many factors that don't directly affect Zoetis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zoetis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zoetis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Zoetis Inc and related stocks such as PetIQ Inc, Emergent Biosolutions, and Bausch Health Companies Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBS | 45.4 M | 41.6 M | 52.9 M | 62.3 M | 93.8 M | 131.6 M | 106.8 M | 125.2 M | 116.4 M | 226.5 M | 549 M | 458.2 M | (34.4 M) | (505.3 M) | (480 M) |
| BHC | (5.2 M) | 988.4 M | 1.9 B | 3.1 B | 4.1 B | 5.1 B | 5.5 B | 3.4 B | 3.2 B | 1.8 B | 2.6 B | 1.9 B | 2.6 B | 2.9 B | 1.6 B |
| NBIX | 500 K | 30.4 M | (2.1 M) | (53.2 M) | (68.3 M) | (99.5 M) | (153.6 M) | (131.4 M) | 40.9 M | 226.6 M | 336.1 M | 218.7 M | 264.6 M | 416.1 M | 436.9 M |
| TEVA | 10.7 M | 4 B | 5.9 B | 4 B | 4.5 B | 5.1 B | 4.7 B | 5.2 B | 3.2 B | 3.2 B | (2.1 B) | 4.4 B | (874 M) | 433 M | 411.4 M |
| HLN | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.9 B | 2.2 B | 2.2 B | 2.4 B | 2.2 B |
| TAK | 252.1 B | 421.8 B | 351.2 B | 405.3 B | 148.4 B | 349.9 B | 389.4 B | 431.3 B | 376.4 B | 687.9 B | 983.7 B | 1.2 T | 1.2 T | 900.3 B | 587.4 B |
| ITCI | (16.3 M) | (16.3 M) | (16.3 M) | (26.2 M) | (30.7 M) | (105.7 M) | (115.3 M) | (98.8 M) | (161.9 M) | (153.5 M) | (230.7 M) | (285.2 M) | (263 M) | (158.9 M) | (166.8 M) |
| CTLT | 291.7 M | 352.8 M | 355.1 M | 253.4 M | 235.6 M | 245.1 M | 243.5 M | 282.3 M | 290.4 M | 397.5 M | 1.1 B | 727 M | 266 M | (284 M) | (269.8 M) |
| AMPH | (20.1 M) | (20.1 M) | 40.3 M | 31.4 M | (17.1 M) | 4.1 M | 30.3 M | (6.2 M) | 7.9 M | 21.1 M | 30.2 M | 111.8 M | 107.5 M | 241.5 M | 253.5 M |
| ALVO | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (125.7 M) | 4 M | (439.8 M) | (484.9 M) | (460.6 M) |
| ASRT | (500 K) | (9.3 M) | (28.3 M) | 13.6 M | 247.2 M | 3.6 M | 131.8 M | 74.5 M | 167.2 M | 105 M | (3.2 M) | 38.8 M | 72.5 M | (222.4 M) | (211.3 M) |
| VTRS | 34.9 M | 1.6 B | 1.1 B | 1.6 B | 1.4 B | 1.2 B | 1.2 B | 1.4 B | 791.2 M | 650.3 M | 2 B | 4.5 B | 6.4 B | 3.5 B | 3.7 B |
| ELAN | 505.6 M | 505.6 M | 505.6 M | 505.6 M | 505.6 M | 505.6 M | 540.4 M | 835.9 M | 640 M | 543 M | (76.8 M) | 409 M | 866 M | (224 M) | (212.8 M) |
Zoetis Inc and related stocks such as PetIQ Inc, Emergent Biosolutions, and Bausch Health Companies Ebitda description
My Equities
My Current Equities and Potential Positions
| Zoetis Inc | ZTS |
| Classification | SRI Sustainable Growth |
| Location | New Jersey; U.S.A |
| Exchange | New York Stock Exchange |
USD 176.71
Additional Tools for Zoetis Stock Analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.